RxDoctor Payments Data

Matthew Thom, MD

Urology · Tuscaloosa, ALNPI 1942234414

Payments from drug & device makers

$4,708in general payments, 2019–2025

Across 213 payments — averaging $22.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$519
  • Endo Pharmaceuticals Inc.$439
  • AbbVie$394
  • Medtronic$324
  • Coloplast$258
  • Boston Scientific$258
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$4,45595%
  • Education$2535%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,708 in reported general payments places this provider in the 55th percentile of 179 urology providers in Alabama.

See all urology providers in Alabama

Medicare billing

Part B allowed, 2024
$148,930
Medicare patients
383
Services billed
9,051

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron64$46,681
MyrbetriqMirabegron37$19,336
Tamsulosin Hcl171$2,861
Finasteride180$2,546
NitrofurantoinNitrofurantoin Macrocrystal107$2,522
Testosterone12$2,189
Oxybutynin Chloride ErOxybutynin Chloride58$940
Testosterone Cypionate32$717
Tolterodine Tartrate ErTolterodine Tartrate12$588
Alfuzosin Hcl ErAlfuzosin Hcl16$426
Dutasteride14$297
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst13$144
Oxycodone Hcl50$138
Cefdinir11$119
Levofloxacin26$46

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$179$46,68164 claims
Astellas Pharma US IncMyrbetriq$519$19,33637 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 179 urology providers in Alabama.

Other urology in Tuscaloosa

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →